Baxter has initiated a nationwide recall of a specific lot of its Cefazolin in Dextrose Injection USP, 2 g/100mL, after cardboard particulate matter was discovered in the solution. This recall affects Lot LD175708, which has an expiration date of February 14, 2027.
The impacted product was distributed across the United States from March 25, 2025, to June 30, 2025. This intravenous medication is primarily used to treat bacterial infections or to prevent them during surgical procedures.
The presence of foreign particles in intravenously administered solutions poses a serious health risk. Potential consequences include pulmonary emboli, blockages in other blood vessels leading to tissue death and organ damage, and phlebitis. Systemically, such particles can activate the immune system, cause organ dysfunction, and lead to the breakdown of blood cells.
To date, Baxter has not received any reports of adverse events directly related to this specific issue. Customers are advised to immediately discontinue use of and return all affected units in accordance with their facility’s established procedures. Baxter is actively contacting customers to provide instructions on identifying and returning the recalled product. For general inquiries, customers can contact the Baxter Healthcare Center for Service at 888-229-0001.